Latest Oncotype DX Stories
BRONX, N.Y., June 3, 2014 /PRNewswire-USNewswire/ -- A test that counts the number of locations in tumor specimens where tumor cells may invade blood vessels predicted the risk of distant spread,
Two Studies Presented at ASCO® Demonstrate Company's Ability to Develop Tests to Predict Disease Aggressiveness Across Various Cancers REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/
New Study Shows Oncotype DX® DCIS Score(TM) Changes Treatment Recommendations for One Out of Three DCIS Patients REDWOOD CITY, Calif., June 1, 2014 /PRNewswire/ -- Genomic Health, Inc.
New Data Presented at ASCO® Annual Meeting Suggest that Genomic Health's Oncotype DX Test May Help Identify Patients That Have the Greatest Opportunity to Benefit from Extended Hormonal Therapy
REDWOOD CITY, Calif., May 23, 2014 /PRNewswire/ -- Genomic Health, Inc.
New Analysis Suggests Oncotype DX Predicts Recurrence Risk After Prostatectomy Regardless of Post-Surgery Treatment REDWOOD CITY, Calif., May 20, 2014 /PRNewswire/ -- Genomic Health,
Oncotype DX® Prostate Cancer Test Enables More Precise Risk Assessment and Significantly Increases Number of Low-Risk Patients Who Can Confidently Choose Active Surveillance REDWOOD
Centralized database of gene-based tests enables easy access to information, improves transparency REDWOOD CITY, Calif., May 14, 2014 /PRNewswire/ -- In response to continued advances
The Diagnostics Marketing Association (DxMA) hosted their annual Global Marketing Summit and Dx Creative Communications Awards Ceremony last month in San Francisco, CA.
13% Increase in Test Volume and 7% Increase in Product Revenue Compared to Prior Year REDWOOD CITY, Calif., May 6, 2014 /PRNewswire/ -- Genomic Health, Inc.
- a slit in a tire to drain away surface water and improve traction.